Bone Meds Could Have Side Effects With Bite
Main Category: Bones / OrthopedicsAlso Included In: Dentistry
Article Date: 09 Aug 2008 - 0:00 PDT
| Patient / Public: | ![]() |
4.5 (8 votes) |
| Healthcare Prof: | ![]() |
4.4 (5 votes) |
Doctors often prescribe bisphosphonates for both osteoporosis as well as certain cancers. And usage has been increasing due to large-scale marketing and advertising to consumers.
Taken orally, these medications (such as Boniva® or Fosamax®) can help promote bone density in women with osteoporosis, and taken intravenously, can help stop the spread of cancer in chemotherapy patients. However, the use of bisphosphonates has also been linked to osteonecrosis of the jaw, more commonly known as "dead jaw."
Osteonecrosis occurs when part of the jawbone essentially dies and becomes exposed. The disease is more prevalent among patients who receive bisphosphonates through an I.V., but Jon Suzuki, D.D.S, Ph.D., M.B.A., professor and director of the graduate program in periodontology at Temple University's Maurice H. Kornberg School of Dentistry, says physicians and dental professionals should still keep a close eye on their patients who take the oral form.
"This is a very complex issue, and our understanding of it continues to grow," said Suzuki. "Both dental and medical professionals need to maintain open lines of communication with each other to ensure the best care for their patients who are taking bisphosphonates."
Previous studies have found between 1 and 10 patients out of 100 who receive bisphosphonates through an IV are at risk of the disease, while only about 1 in 100,000 patients taking the oral form are at risk.
Existing research suggests that taking these medications orally for more than three years or intravenously for more than six months could disturb the balance between bone cells that produce calcium and those that remove calcium. This condition can lead to oral health problems including loose teeth, jaw and gum pain, swelling and infection, numbness and gum loss.
Patients who have existing dental problems or have just had dental work and are taking bisphosphonates are also at higher risk for osteonecrosis. Suzuki advises that these patients have a full dental exam to determine the health of their jaw and what level of bisphosphonates would be appropriate.
"If a patient needs dental surgery, the dentist and treating physicians need to decide whether other treatment options, including systemic antibiotics or antimicrobial mouth rinses, can help reduce the risk of osteonecrosis," he said.
Temple University
301 University Services Bldg.1601 N Broad St.
Philadelphia, PA 19122
United States
http://www.temple.edu
Visit our bones / orthopedics section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/117763.php>
APA
http://www.medicalnewstoday.com/releases/117763.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



